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Objectives: Patients with dementia due to Alzheimer’s disease (AD) are often cared 
for by family members who experience physical, psychological, social, and financial 
burdens associated with provision of care. This study quantifies the impact of caregiv-
ing in Brazil and helps identify characteristics associated with caregiving. MethOds: 
Data were analyzed from the 2012 National Health and Wellness Survey (NHWS) 
in Brazil (n = 12,000), an Internet-based survey of adults (aged 18+), using strati-
fied random sampling (by sex and age) to ensure demographic representation of the 
Brazil adult population. Caregivers were compared with non-caregivers on select 
comorbidities considered potential outcomes of caregiving, plus sociodemographic 
characteristics, health characteristics and behaviors, and Charlson comorbidity index 
(CCI) scores. Binary logistic regression models assessed comorbidities associated with 
caregiving, adjusting for potential confounds (CCI, age, gender, education, income, 
insurance, and marital status). Results: Among 10,853 respondents (caregivers 
[n= 209]; non-caregivers [n= 10,644]), caregivers were on average 42.1 years old, and 
53% were female, 52% married/living with a partner, 87% insured, and 42% living with 
1+ children in the household. Caregivers vs. non-caregivers were more frequently 
obese, smokers, insured, employed, and with college education or above, and they 
had higher CCI scores and higher income, all p < .05. Adjusting for covariates, caregiv-
ing was associated with significantly increased risk of depressive symptoms (odds 
ratio [OR] = 2.008), major depressive disorder (OR= 1.483), anxiety (OR= 1.714), insomnia 
(OR= 1.644), hypertension (OR= 1.584), pain (OR= 1.704), and diabetes (OR= 2.103), all 
p< .015. cOnclusiOns: This is the first study on caregivers for persons with demen-
tia in Brazil using a large dataset (NHWS). Being a caregiver (compared with non-
caregiver) is a predictor of overall psychiatric and clinical disorders in this sample. The 
online survey format provides certain sampling advantages but may under-represent 
caregivers without access/comfort with online technology. Direct treatment and poli-
cies to help caregivers are needed in Brazil.
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Objectives: Despite the existence of standardized medical criteria, clinical diagno-
sis of Alzheimer’s disease remains difficult. Lack of diagnostic certainty or possible 
distress related to positive results could limit application of new testing technolo-
gies. Independent of the therapeutic value of prevention or cure, however, diagnostic 
information could have value in informing contingency planning or have intrinsic 
value: the value of “just knowing”. This paper aims to quantify respondents’ prefer-
ences for obtaining AD diagnostic tests and to estimate the perceived value of AD 
test information. MethOds: Discrete-choice experiment (DCE) and contingent-
valuation (CV) questions were administered to N= 1301 respondents aged 60 years 
or older in Germany and the United Kingdom. 12 pairs of virtual AD diagnostic tests 
were presented (defined by test type, test precision defined by false-positive or false-
negative test results, and test cost) and a no-test alternative. DCE questions were 
based on a predetermined experimental design. A double-bounded, dichotomous-
choice CV question was used to further elicit willingness to take an AD test and pay 
for it. Choice data of respondents interested in taking a test were analyzed using 
random-parameters logit. A probit model characterized respondents who were not 
willing to take a test. Results: Most respondents in both countries had a posi-
tive value for AD diagnostic test information. Most respondents who indicated an 
interest in testing in Germany (N= 631) and the UK (N= 670) preferred brain imaging 
without radioactive marker, followed by brain imaging with radioactive marker 
and then spinal tap. Diagnostic tests with better precision were preferred. German 
respondents had relatively greater heterogeneous preferences and lower money-
equivalent values for test features compared to UK respondents. cOnclusiOns: 
Respondents preferred less invasive diagnostic procedures and tests with higher 
accuracy. Diagnostic test accuracy was more important than test type. Respondents 
expressed a willingness to pay up to € 700 to receive a less invasive test with the 
highest accuracy.
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Objectives: The aim of this study was to understand the current impact of partial 
onset seizures (POS) on health outcomes and costs. MethOds: Patients were identi-
fied from the 2010 & 2013 5EU and 2011-2012 Brazil National Health and Wellness 
Survey, a nationally represented, internet-based survey of adults (18+ years). 
Patients self-reported a diagnosis of epilepsy with POS and were categorized into 
≥ 1 seizure per week, 1-3 seizures per month, 1-4 seizures per year, < 1 seizure per 
year (reference). Patients completed the SF-36v2 (mental (MCS), physical component 
summary (PCS)), SF-6D (health utility), Work Productivity and Activity Impairment 
Questionnaire and reported on resource utilization in the past six months. Costs 
were estimated from the literature. Generalized linear regression analyses were 
conducted controlling for covariates (e. g., age, gender, marital status, comorbidities, 
years diagnosed with epilepsy). Results: There were 175 patients in the 5EU and 
32 in Brazil, 11.1% reported ≥ 1 seizures/week, 7.7% reported 1-3 seizures/month, 
26.1% 1-4 seizures/year, and 55.1% < 1seizures/year. MCS, PCS, utilities, productivity 
categorized into three groups: placebo, PR-fampridine responders (those with 
a mean improvement from baseline in the 12-item MS walking scale [MSWS-
12] of ≥ 8 points over 24 weeks), and PR-fampridine nonresponders (those with 
worsening, no change, or < 8 points improvement in MSWS-12). Changes from 
baseline were calculated for the EQ-5D utility index and visual analogue scale 
(VAS) by visit and over the 24 weeks. Within-group and pairwise comparisons 
were assessed based on the least square (LS) means using analysis of covariance 
(ANCOVA) models adjusting for baseline EQ-5D scores. Results: The placebo 
patients (n= 64), responders (n= 33), and nonresponders (n= 35) were similar in 
baseline age, race, weight, and number of relapses in the past 1 and 2 years. 
The responders had higher mean baseline EQ-5D utility (0.56 vs. 0.51 and 0.52, 
respectively) and VAS (62.9 vs. 59.1 and 60.5, respectively) scores than the placebo 
patients and nonresponders. Over the 24 weeks, the EQ-5D utility score improved 
in the responders (mean change: 0.06, 95% CI: [0.01, 0.12]) but worsened in the 
placebo patients (mean change: -0.03,95% CI: [-0.07, 0.01]) and nonresponders 
(mean change: -0.07,95% CI: [-0.12, -0.02] ). Similar trends were observed in the VAS 
scores although the differences within groups were generally not statistically sig-
nificant. cOnclusiOns: PR-fampridine 10 mg tablets demonstrated significantly 
greater improvement in QoL among responders, despite starting from higher base-
line EQ-5D scores, than the placebo or nonresponder groups.
PND65
the burDeN of PrImary geNeralIzeD toNIc-cloNIc seIzures IN euroPe 
aND the uNIteD states: aN aNalysIs of the NatIoNal health aND 
wellNess survey
Gupta S.1, Forsythe A.2, Pomerantz D.1, Tsong W.2
1Kantar Health, Princeton, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA
Objectives: Many prescription medications are available to treat Primary 
Generalized Tonic-Clonic (PGTC) seizures. The objective is to understand the 
impact of PGTC on health outcomes. MethOds: Data from the 2011-2013 U.S. and 
2010 & 2013 5E.U. National Health and Wellness Survey (NHWS) were analyzed. 
The NHWS is self-administered, internet-based survey of a nationwide sample of 
adults (18+ years) stratified to represent the demographic composition of each 
country. Patients self-reported a diagnosis of epilepsy with PGTC and were grouped 
as ≥ 1 seizure per week, 1-3 seizures per month, 1-4 seizures per year, < 1 seizure 
per year (reference). Patients provided information on health status (mental (MCS), 
physical component summary (PCS), and SF-6D (health utility) from the SF-36v2), 
resource utilization in the past six months and productivity loss (Work Productivity 
and Activity Impairment Questionnaire). Costs were estimated from the literature. 
Regression analyses were conducted controlling for covariates (e. g., age, gender, 
marital status, comorbidities, years diagnosed with epilepsy). Results: There were 
782 patients in the U.S. and 418 in the 5EU. In both geographies the proportion of 
employed respondents decreased as frequency of seizures increased. Over 75% of 
patients in both geographies were taking a prescription medication for epilepsy. 
After adjustments, patients reporting < 1 seizure per year had greater PCS, health 
utilities, lower activity impairment, fewer emergency room visits and lower total 
direct costs compared to the other three seizure groups (p< 0.05 both geographies). 
Among employed patients, patients reporting < 1 seizure per year had the lowest 
overall work impairment (p< 0.05 both geographies). For all employable patients 
(18-60 years) indirect costs were highest for the ≥ 1 seizure per week group (p< 0.05 
both geographies). cOnclusiOns: Results suggest a significantly higher economic 
and humanistic burden in patients with more frequent seizures. PGTC patients are 
very much in need of newer treatment options.
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Objectives: To describe the characteristics and burden of caregivers and patients 
affected by relapsing-remitting multiple sclerosis (RRMS), and to describe their sat-
isfaction with treatment. MethOds: Multicenter, observational, cross-sectional 
study in RRMS patients≥ 18 years (y), treated for ≥ 1y. Burden was assessed with 
the Zarit Burden Interview. Other measures were: Center for Epidemiologic Studies 
Depression Scale, short form (CESD-7); and treatment satisfaction of caregivers (ad-
hoc questionnaire) and patients (Treatment Satisfaction Questionnaire for Medication 
(TSQM)). Results: We included 180 patients (mean (SD) age 41 (11) y, 66% female) and 
caregivers (47 (12) y, 56% female, 67% economically active). Most caregivers were rela-
tives (59% partner; 25% parent; 9% brother or sister) and lived with the patient (86%); 
37% helped with the medication. Median (Q1, Q3) time since diagnosis was 7 (4,10) y 
and between diagnosis and first treatment, 0.3 (0.2, 1.3) y. Most patients received 
monotherapy with interferon beta (51%), glatiramer acetate (20%), natalizumab (14%) 
or fingolimod (7%); 15.6% received ≥ 2 drugs. Median EDSS was 2.5 (1,4). According to 
the Zarit Interview, 19% of caregivers had some degree of burden (median: 10 (7,15)). 
Factors associated with burden were: EDSS (mean (SD) in caregivers with burden vs 
without burden, respectively: 4.0 (2.1) vs 2.6 (1.9), p< 0.0005), years of caregiving (mean: 
4.0 (4.5) vs 2.7 (4.5) y, p= 0.005), daily hours dedicated to patient (10.8 (12.1) vs 5.8 (4.6) 
hours, p= 0.038), and > 1 drug (39% of burden when patients take≥ 2 drugs vs 16% with 
monotherapy, p= 0.004). Other caregiver’s characteristics (age, gender, professional 
activity, relationship with patient or cohabitation) were not significantly associated. 
28.2% of caregivers had depression (CESD-7≥ 15). Both patients (90% satisfied or very 
satisfied according to the TSQM) and caregivers (mean of 7.6 (2.3) on a scale from 
0-10 [maximum satisfaction]) were quite satisfied with treatment. cOnclusiOns: 
In the RRMS population with moderate disability, around 2 in 10 caregivers have some 
degree of burden, and 1 in 4 suffer depression. The burden increases proportionately 
with disease severity and number of medications administered. Overall, patients and 
caregivers are satisfied with treatment.
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sents methods to evaluate working ability and quality of life in natalizumab-treated 
RRMS patients. MethOds: A non-interventional study was performed in Germany. 
Patients treated with natalizumab for a maximum of three months prior to baseline 
were eligible for study participation. Demographic and occupational information 
was collected; DSS and EQ-5D-questionnaires were used. Data were collected at 
baseline, after 6 months and after 12 months. Main objective was to evaluate pro-
ductivity per year, by using the formula: (working hours per day*5 days per week*46 
working weeks a year) - (days absent from work*working hours per year). To assess 
health economic cost savings, productivity has been valued monetarily by calcu-
lating a daily rate of working costs. Subgroup analysis divides the study popula-
tion into employed, unemployed, patients with statutory sick pay and students. 
Analyses of variance and subsequent post hoc tests will be performed to identify 
subgroup differences. Results: Of 95 patients included by January 2014, 46.3% 
were employed. Average hours worked/day were 5.3 hours (employed: 6.5 hours); 
average number of days absent from work during the past half-year was 17.4 days 
(employed: 16.5 days). Calculated productivity per 6 months results in 569.6 hours 
(employed: 661.0), meaning 6,5540.40€ (employed: 7,634.55€ ) in monetarily valued 
productivity. cOnclusiOns: This non-interventional study aimed at providing new 
insights in the therapy of RRMS patients treated with natalizumab. The study’s 
intention was to show how an increase in working hours in employed patients as 
well as a decrease in days absent from work can lead to an increase in productivity. 
Study was funded by Biogen Idec.
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Objectives: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing–remitting MS. The phase 3 TENERE (NCT00883337) study comparing 
teriflunomide with subcutaneous interferon beta-1a (sc IFNβ -1a) did not meet its 
primary endpoint (superiority of teriflunomide vs sc IFNβ -1a on time to treatment 
failure) although there was no difference in annualized relapse rate between teriflu-
nomide 14 mg and sc IFNβ -1a. The objective of the current analysis was to compare 
patient treatment satisfaction of teriflunomide with that of sc IFNβ -1a. MethOds: 
Randomized patients (n= 324) received once-daily teriflunomide 14 mg or 7 mg or 
sc IFNβ -1a three times per week; the study was completed 48 weeks after the last 
patient was randomized. Patient satisfaction with treatment was assessed as a 
secondary endpoint using the Treatment Satisfaction Questionnaire for Medication 
(TSQM) version 1.4, a validated generic questionnaire with scores for effective-
ness, side-effects, convenience, and global satisfaction. A mixed-effect model with 
repeated measures was used to analyze TSQM scores at Week 48. Magnitude of 
effects was assessed using effect size (ES), defined as the difference in treatment 
effect divided by standard deviation. The ES differences were ranked as follows: < 0.2, 
negligible; ≥ 0.2–< 0.5, small; ≥ 0.5–≤ 0.8, moderate; > 0.8, high. Results: At Week 48, 
TSQM values showed significantly better patient satisfaction in the teriflunomide 
14-mg group vs the IFNβ -1a group in three domains (side-effects, P< 0.0001; con-
venience, P< 0.0001; global satisfaction, P= 0.02), with no perceived difference on 
effectiveness (P= 0.28). High ES values favoring teriflunomide 14 mg vs IFNβ -1a were 
seen with side-effects (1.09) and convenience (1.81), with a smaller ES for global 
satisfaction (0.39). cOnclusiOns: A significant and meaningful improvement in 
treatment satisfaction for teriflunomide 14 mg vs IFNβ -1a was observed with regards 
to side-effects, convenience, and global satisfaction, which may potentially improve 
treatment adherence and outcomes in clinical practice.
NeurologIcal DIsorDers – health care use & Policy studies
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Objectives: Analyze real-life AED treatment sequencing in the UK using prescrip-
tion data from the Clinical Practice Research Datalink (CPRD), and compare it to 
the 2012 National Institute for Health and Care Excellence (NICE) clinical guide-
lines. MethOds: Patients were included if they had an epilepsy diagnosis and an 
AED prescription between January, 2009 and January, 2014. Patients who entered the 
database untreated were followed from first AED prescription following an epilepsy 
diagnosis, for up to five lines of treatment until being censored at the end of reg-
istration, death, or end of data coverage. Follow-up time could differ substantially 
between patients. AED treatment changes were classified as add, switch, or stop. 
The number of patients per treatment line was calculated for each individual AED 
combination and each regimen, grouped as Monotherapy, Polytherapy, and “No 
AED”. Results: Overall, 8931 patients went through 2469 unique AED treatment 
sequences; 97.1% were started on Monotherapy. 30.8% of patients stayed on their 
first Monotherapy until censored. 16.5% of initial Monotherapy patients switched 
to a second Monotherapy; 27% went to “No AED”; 25.7% progressed to Polytherapy. 
The first treatment line was consistent with NICE guidelines for 70.4% of patients. 
Thereafter, 14.7% of patients were treated within guidelines in the first 2 lines. 
The main divergence from guidelines involved prescribing Polytherapy or “No 
AED” rather than a second monotherapy in line 2. Largely consistent with NICE, 
the most frequent (87.1%) initial monotherapy AEDs were valproic acid (30.1%), 
lamotrigine (22.8%), carbamazepine (17.5%), levetiracetam (10.3%), and phenytoin 
loss and resource were similar in Brazil and the 5EU (all p> 0.05). After adjustments 
(combined 5EU and Brazil), as the number of seizures decreased, PCS (≥ 1 seizures/
week: 40.9; 1-3 seizures/month: 41.7; 1-4 seizures/year: 46.9; < 1seizures/year: 48.4) 
and health utilities (≥ 1 seizures/week: 0.58; 1-3 seizures/month: 0.63; 1-4 seizures/
year: 0.63; < 1seizures/year: 0.69) increased. As the number of seizures decreased, 
activity impairment (≥ 1 seizures/week: 58.6%; 1-3 seizures/month: 51.1%; 1-4 sei-
zures/year: 35.7%; < 1seizures/year: 25.5%), emergency room visits and hospitaliza-
tions decreased. In Europe direct and indirect costs were highest for the ≥ 1 seizure/
week group. cOnclusiOns: POS burden was similar in Europe and Brazil. As the 
number of seizures increased, economic and humanistic burden increased. Even 
with the large number of treatment options available, patients and the health care 
system need additional choices to reduce the frequency of seizures.
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Objectives: Mobility impairments affect most multiple sclerosis (MS) patients 
(93%), yet many patients (~40%) “rarely or never” discuss trouble walking with a 
health care provider (HCP). To facilitate patient-HCP dialogue and early identifica-
tion of mobility impairments, the Early Mobility Impairment Questionnaire (EMIQ) 
was developed based on qualitative research with patients diagnosed with MS and 
in collaboration with key opinion leaders. To minimize the burden associated with 
administration of the EMIQ, psychometric analyses were applied to the initial draft 
to produce a parsimonious yet robust instrument. MethOds: The EMIQ’s psycho-
metric performance was evaluated in a multi-center, prospective, observational 
study in subjects with an Expanded Disability Status Scale (EDSS) score of 2.0 to 
6.0. Iterative exploratory factor analysis (EFA) was used to guide item reduction; 
subsequently, an item response theory (IRT) graded response model was applied to 
confirm the robustness of the instrument. Logistic regression analyses (using EDSS 
scores) were used to confirm discriminatory power. Results: In total, 124 subjects 
with moderate MS (EDSS mean score = 4.2) were included in the study. Discriminant 
validity, factor analysis, and IRT modeling identified six items for reduction. The 
resulting 9-item scale had one strong underlying domain (first eigenvalue explained 
60% of variance). The information curve showed sufficient sensitivity (I> 3.3 for 
-2.6≤ θ ≤ 2.4) throughout the scale (mild to severe), with the most precise informa-
tion provided at ½ SD above the mean (I= 12 at θ = 0.4). Logistic regression showed 
that the EMIQ was able to discriminate between patients with and without walk-
ing impairment (p< 0.05). cOnclusiOns: The psychometric analyses resulted in a 
streamlined scale that is appropriate for the screening of subjects experiencing early 
mobility impairments due to MS. In addition to a potential role in guiding clinical 
assessment and intervention, the EMIQ may also prove useful in the longitudinal 
assessment of mobility, as patients’ conditions decline.
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Objectives: The impact of Cognitive Impairment (CI) on Health Related Quality 
of Life (HRQoL) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) 
is becoming a field of study increasingly relevant due to its implications on the 
effectiveness and quality research. Since the studies reviewed highlight contra-
dictory results, the aim of this study was to determine the predictive value of CI 
and other correlated factors on HRQoL in a sample of RRMS patients. MethOds: 
Observational, cross-sectional and multicenter study at 21 Neurology Departments 
in Spain. Multiple linear regression analysis (stepwise) was carried out to 
assess if HRQoL (EQ-5D scores) was predicted by CI (Brief Repeatable Battery of 
Neuropsychological Tests, BRB-N), physical disability (Expanded Disability Status 
Scale -EDSS), depression (Beck Depression Inventory-BDI-II) and disease duration 
(years diagnosed). Bivariate, partial and semi-partial correlations and multicol-
linearity analysis were performed to control confounding factors. Results: We 
included 291 RRMS patients (71.50% female), mean age 41.65 years (SD= 10.18). The 
mild disability group (EDSS 0-3) included 152 (52.20%) patients and the moder-
ate disability group (EDSS 3.5-5.5) included 139 patients (47.80%). All correlations 
between EQ-5D scores and BRB-N, BDI-II, EDSS and disease duration variables were 
statistically significant (p< 0.01), not multicollinearity detected. The results of the 
regression analysis indicated that two predictors explained 56.9% of the HRQoL 
variance (Adjusted R squared= 0.569, F= 187,251, p< 0.01). It was found that depres-
sion significantly predicted HRQoL (Beta= -0.587, p< 0.01), as did physical disability 
(Beta= -0.315, p< 0.01). cOnclusiOns: The results showed a weak predictive value 
of CI (measured with the BRB-N battery) in HRQOL scores while depression and 
psychical disability were important predictors. Future research is needed in order 
to clarify the relationship between CI and HRQoL.
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Objectives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease representing the most common chronic neurological disorder in 
young adults. RRMS usually leads to permanent disability and as a result is a major 
cause of reduced working capacity due to neurological diseases. This abstract pre-
